Zenas BioPharma, Inc.
zenasbio.comWhat Do They Do?
Develops antibody and oral drug candidates for patients with autoimmune diseases.
10-K for FY2025, filed Mar 16, 2026We are a clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of…View ↗
Our lead I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly…View ↗
In addition to obexelimab, we are developing orelabrutinib, a Bruton’s Tyrosine Kinase inhibitor (“BTK”), for progressive forms of multiple…View ↗
ZB021 is an oral small molecule IL-17AA/AF inhibitor designed to block both IL-17AA homodimer and IL-17AF heterodimer signaling, ZB022 is…View ↗
How Do They Make Money?
Has received upfront fees for sublicensing product rights and may receive additional payments when development or commercial milestones are reached, plus royalties on sales.
10-K for FY2025, filed Mar 16, 2026
$10M
-
10-K for FY2025, filed Mar 16, 2026
$10M ↗
Do Revenues Turn Into Profits?
No. It lost $377.7M in FY2025.
10-K for FY2025, filed Mar 16, 2026
−$383.1MView ↗
10-K for FY2025, filed Mar 16, 2026
−$377.7MView ↗
10-K for FY2025, filed Mar 16, 2026
−$172.4MView ↗
How Are They Changing?
-
Aug 13, 2026
CFO to transition to strategic adviser role
Sources
8-K, filed Aug 13, 2026
- CFO to transition to Strategic Advisor to the Board Chair at the end of September -View ↗
Who Do They Compete With?
Competes with Amgen, Sanofi, Acepodia, F. Hoffmann-La Roche, Novartis, TG Therapeutics, Biogen, Bayer, Merck, Teva Neuroscience, Banner Life Sciences, Janssen Pharmaceuticals, Bristol Myers Squibb, Immunic Therapeutics, AB Science, GSK, AstraZeneca, RemeGen, UCB, and AbbVie
10-K for FY2025, filed Mar 16, 2026Uplizna® (inebilizumab-cdon), an anti-CD19 antibody marketed by Amgen Inc.;View ↗
Loading...
